Shutdown
Jul 2026Endpoints reported the company appears to be winding down after an employee LinkedIn post; no formal shutdown filing was located.
SourceArpeggio Bio develops drugs targeting transcription factors using AI…
Company research
Public company, workplace, funding, and market signals
Overview
Arpeggio Bio is a Boulder-based preclinical biotech developing transcriptomics-driven therapies and drug-discovery tools to tackle undruggable transcription factors, especially in cancer, chronic kidney disease, and neurodegeneration. Public reporting in July 2026 suggests the company may be winding down.
Primary product
A proprietary transcriptomics / chemotranscriptomics drug-discovery platform (GRETA)
Founded
2017
Headquarters
Boulder, Colorado, United States
Team size
10-20
Work style
Onsite
Industry
Biotechnology
Sub-industry
Preclinical therapeutics / transcriptomics-enabled drug discovery
Offices
Open Positions
0 jobs at Arpeggio Bio
No open positions
Check back later for new openings